10% 2-OHp-b-cyclodextrin

<strong>2-OHp-b-cyclodextrin 10%</strong>_x000D_ <strong>Catalog number:</strong> K1010005D_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 25 mL_x000D_ <strong>Molecular Weight or Concentration:</strong> 10% (w/v)_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> versatile tools in molecular assemblies, enhancement of solubility and organic synthesis_x000D_ <strong>Storage:</strong> 2-8°C_x000D_ <strong>Keywords:</strong> (2-hydroxypropyl)-b-cyclodextrin, (2-hydroxypropyl)-β-cyclodextrin_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Sun H, Zong H, Wu G. 2‑Hydroxypropyl‑β‑cyclodextrin blocks autophagy flux and_x000D_ triggers caspase‑8‑mediated apoptotic cascades in HepG2 cells. Mol Med Rep. 2020_x000D_ Sep;22(3):1901-1909._x000D_ _x000D_ 2: Kao ML, Stellar S, Solon E, Lordi A, Kasica N, Swain G, Bagel JH, Gurda BL,_x000D_ Vite CH. Pharmacokinetics and distribution of 2-hydroxypropyl-β-cyclodextrin_x000D_ following a single intrathecal dose to cats. J Inherit Metab Dis. 2020_x000D_ May;43(3):618-634._x000D_ _x000D_ 3: Leonis G, Christodoulou E, Ntountaniotis D, Chatziathanasiadou MV,_x000D_ Mavromoustakos T, Naziris N, Chountoulesi M, Demetzos C, Valsami G, Damalas DE,_x000D_ Tzakos AG, Thomaidis NS, Karageorgos V, Liapakis G. Antihypertensive activity_x000D_ and molecular interactions of irbesartan in complex with 2-hydroxypropyl-β-_x000D_ cyclodextrin. Chem Biol Drug Des. 2020 Jul;96(1):668-683._x000D_ _x000D_ 4: Ding Y, Pang Y, Vara Prasad CVNS, Wang B. Formation of inclusion complex of_x000D_ enrofloxacin with 2-hydroxypropyl-<i>β</i>-cyclodextrin. Drug Deliv. 2020_x000D_ Dec;27(1):334-343._x000D_ _x000D_ 5: Pons-Faudoa FP, Sizovs A, Di Trani N, Paez-Mayorga J, Bruno G, Rhudy J,_x000D_ Manohar M, Gwenden K, Martini C, Chua CYX, Varchi G, Marzinke MA, Grattoni A._x000D_ 2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a_x000D_ nanofluidic implant for HIV pre-exposure prophylaxis. J Control Release. 2019_x000D_ Jul 28;306:89-96._x000D_ _x000D_ 6: Stappaerts J, Berben P, Cevik I, Augustijns P. The effect of 2-hydroxypropyl-_x000D_ β-cyclodextrin on the intestinal permeation through mucus. Eur J Pharm Sci. 2018_x000D_ Mar 1;114:238-244._x000D_ _x000D_ 7: Liu X, Ding D, Chen GD, Li L, Jiang H, Salvi R. 2-Hydroxypropyl-β-_x000D_ cyclodextrin Ototoxicity in Adult Rats: Rapid Onset and Massive Destruction of_x000D_ Both Inner and Outer Hair Cells Above a Critical Dose. Neurotox Res. 2020_x000D_ Oct;38(3):808-823._x000D_ _x000D_ 8: Yu SC, Chen TC, Hou YT, Wan L, Tsai FJ, Tsai Y. β-Sitosterol-2-hydroxypropyl-_x000D_ β-cyclodextrin inclusion complex: Characterization and inhibitory effect on_x000D_ adipogenesis in 3T3-L1 pre-adipocytes. Steroids. 2018 Dec;140:196-201._x000D_ _x000D_ 9: Burga-Sánchez J, Ferreira LEN, Volpato MC, Cabeça LF, Braga M, Fraceto LF, de_x000D_ Paula E, Groppo FC. Physicochemical characterization and cytotoxicity of_x000D_ articaine-2-hydroxypropyl-β-cyclodextrin inclusion complex. Naunyn Schmiedebergs_x000D_ Arch Pharmacol. 2020 Jul;393(7):1313-1323._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/31991574/">10: Han D, Han Z, Liu L, Wang Y, Xin S, Zhang H, Yu Z. Solubility Enhancement of_x000D_ Myricetin by Inclusion Complexation with_x000D_ Heptakis-<i>O</i>-(2-Hydroxypropyl)-β-Cyclodextrin: A Joint Experimental and_x000D_ Theoretical Study. Int J Mol Sci. 2020 Jan 24;21(3):766. </a>_x000D_ _x000D_ <strong>Products Related to 2-OHp-b-cyclodextrin 10% </strong><a href="https://moleculardepot.com/product-category/Chemicals/">: Chemicals</a>